Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCapital Bluecross Value Plus Formulary Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCapital BluecrossPolicy N/A

    Value Plus Formulary — Prescription Drug Formulary and Utilization Management

    Customize your policy alerts

    Sign up for all Capital Bluecross policy alerts

    Know when Capital Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs Capital Blue Cross's Value Plus prescription drug formulary, utilization management (prior authorization, step therapy, quantity limits), specialty drug distribution, and related pharmacy procedures for members and providers.

    Policy Summary
    PayerCapital Bluecross
    PolicyValue Plus Formulary — Prescription Drug Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a nonformulary consideration (formulary exception) request on behalf of the member when seeking coverage for a drug not listed on the formulary.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Value Plusformulary name maintained by P&T Committee
    30-daystandard supply limit for specialty drugs
    30/90-daytypical supply durations
    Accredospecialty pharmacy provider
    PA • ST • QLLutilization management tools used

    Coverage Criteria and Limits

    Coverage Conditions

    Coverage determinations and limits — drugs are covered only when all of the following conditions are met:

    FDA approval: Drug is approved by the U.S. Food and Drug Administration as evidenced by an NDA, ANDA, or BLA on file, unless legal requirements or group-specific benefits supersede.FDA approval

    Drugs that are not FDA‑approved are not covered under the prescription drug benefit; providers may submit a nonformulary exception if they believe a non‑FDA or unlisted drug is medically necessary.

    Formulary status or approved exception: Drug is listed on the plan formulary OR a nonformulary (formulary exception) has been approved through the nonformulary consideration process.N/A

    Providers must submit nonformulary consideration requests on behalf of members for drugs not on the formulary.

    Policy Summary
    PayerCapital Bluecross
    PolicyValue Plus Formulary — Prescription Drug Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a nonformulary consideration (formulary exception) request on behalf of the member when seeking coverage for a drug not listed on the formulary.
    SourceLink
    On This Page
    Coverage Criteria and LimitsFormulary Listings and CodingProvider Requirements and Utilization ManagementPolicy BackgroundDefinitions and AbbreviationsStep Therapy RulesQuantity Level LimitsSpecialty Pharmacy and Distribution
    Utilization management requirements: Any required utilization management (prior authorization, step therapy, or quantity level limits) for the drug have been satisfied per the member's plan prior to coverage.N/A

    If a prior authorization, step therapy, or quantity limit applies and is not met, coverage may be denied; drugs commonly subject to these controls are indicated on the drug list.

    Supply and dispensing limits: Requested dispensing quantity is within the plan's supply limits (most drugs up to a 30‑day supply; some maintenance drugs up to 90 days; specialty drugs limited to a 30‑day supply).30-day (specialty) or up to 90-day (maintenance where allowed)

    Members are responsible for the full cost if dispensed quantity exceeds plan dispensing limits.

    Contractual exclusions and coverage rules: Drug is not excluded by the member's specific benefit design (examples of possible exclusions include appetite suppressants, cosmetic agents, certain erectile dysfunction or anti‑obesity agents, experimental/investigational or off‑label uses, non‑self‑administered injectables, and some non‑prenatal vitamins or OTC equivalents).N/A

    Some employers may add or remove coverage for these categories; check the member's Certificate of Coverage for plan‑specific exclusions.

    Examples of contractual exclusions include drugs intended as appetite suppressants (weight loss), drugs used for cosmetic purposes (e.g., for wrinkles or hair loss), anti-obesity agents (for example, Wegovy), erectile dysfunction drugs, therapies used for experimental or investigational purposes (including off‑label use), non‑self‑administered injectable drugs, certain non‑prenatal vitamins, and products that have available OTC equivalents.

    Prescription drugs not listed on the formulary are not covered unless a nonformulary consideration (formulary exception) is approved. Providers must submit a nonformulary consideration request on behalf of the member to seek coverage for a nonformulary drug.

    This excerpt is a formulary product listing and does not state any explicit coverage exclusions within the text shown.

    No explicit coverage exclusions are identified in this segment; the content is a listing of product names and strengths.

    The provided chunk contains formulary entries for antidiabetic products and does not include explicit coverage exclusion language.

    These chunks list insulin and other antidiabetic product presentations and do not state any explicit contractual coverage exclusions.

    This segment enumerates endocrine and metabolic agents (product names and strengths) and does not include explicit coverage exclusion statements.

    The excerpt is a drug and formulation listing and contains no explicit coverage exclusions; it does not provide coverage criteria for the items shown.

    Drugs that are not FDA‑approved or that are experimental/investigational (including off‑label use) are identified as not covered under the prescription drug benefit unless otherwise specified.

    This segment lists medication strengths and formulations (e.g., dexamethasone) and does not include any explicit statements labeling therapies as not medically necessary.

    No explicit 'not medically necessary' determinations are stated in this excerpt; content is limited to product listings and pack descriptions.

    The antidiabetic drug listings in this chunk do not contain explicit 'not medically necessary' language.

    Formulary Listings and Coding

    Listed drug products (extracted names/strengths)mixed
    ledipasvir-sofosbuvir 45-200 mgHARVONI ledipasvir-sofosbuvir tab 45-200 mg
    glecaprevir-pibrentasvir 100-40 mgMAVYRET glecaprevir-pibrentasvir tab 100-40 mg
    pibrentasvir 50-20 mgpibrentasvir pellet pack 50-20 mg
    nevirapine 50 mg/5 mLNEVIRAPINE nevirapine suspension 50 mg
    etravirine 25/100/200 mgINTELENCE etravirine tab 25 mg; 100 mg; 200 mg
    raltegravir 100 mg (packet)ISENTRESS raltegravir potassium packet for suspension 100 mg
    raltegravir 600 mgISENTRESS HD raltegravir potassium tab 600 mg
    dolutegravir-rilpivirine 50-25 mgJULUCA dolutegravir-rilpivirine tab 50-25 mg
    lopinavir-ritonavir soln 400-100 mg/mLKALETRA lopinavir-ritonavir solution 400-100 mg/mL
    molnupiravir 200 mgLAGEVRIO molnupiravir cap 200 mg
    1–10 of 24
    1/3
    Antiviral agents (partial)mixed
    sofosbuvir tab 200 mg; 400 mgSOVALDI sofosbuvir tab 200 mg; 400 mg
    sofosbuvir pellet packSOVALDI sofosbuvir pellet pack
    sofosbuvir-velpatasvir tabSOFOSBUVIRNELPATASVIR sofosbuvir-velpatasvir tab
    tenofovir disoproxil fumarate oral powder 40 mg/gmVIREAD tenofovir disoproxil fumarate oral powder 40 mglgm
    HIV/HCV agents (partial)mixed
    elvitegravir-cobicistat-emtricitabine-tenofovir DF tabSTRIBILD elvitegrav-cobic- emtricitab-tenofovdf tab
    sofosbuvir-velpatasvir-voxilaprevir tab 400-100-100 mgVOSEVI sofosbuvir-velpatasvir- voxilaprevir tab 400-100-100 mg
    lenacapavir sodium tab therapy 300 mg packSUNLENCA lenacapavir sodium tab therapy 300 mg pack
    Antimalarials, Anthelmintics, Anti-infectives (partial)mixed
    zidovudine syrup 10 mg/ml; zidovudine tab 300 mgzidovudine syrup 10 mglml (Retrovir); zidovudine tab 300 mg
    linezolid susp 100 mg/5ml; linezolid tab 600 mglinezolid for susp 100 mglsml (Zyvox); linezolid tab 600 mg (Zyvox)
    atovaquone-proguanil HClatovaquone-proguanil hcl
    chloroquine phosphate tabchloroquine phosphate tab
    hydroxychloroquine sulfate tab 100 mg; 200 mg; 300 mg; 400 mghydroxychloroquine sulfate tab 100 mg; 200 mg; 300 mg; 400 mg (Plaquenil)
    nitrofurantoin macrocrystalline cap 25 mg; 50 mg; monohydrate 100 mgnitrofurantoin macrocrystalline cap 25 mg; 50 mg; nitrofurantoin monohydrate macrocrystalline cap 100 mg (Macrobid)
    mefloquine HCl tab 250 mg; primaquine phosphate tab 26.3 mgmefloquine hcl tab 250 mg; primaquine phosphate tab 26.3 mg (15 mg base)
    pyrimethamine tab 25 mg; quinine sulfate cap 324 mgpyrimethamine tab 25 mg; quinine sulfate cap 324 mg (Qualaquin)
    albendazole tab 200 mg; praziquantel tab 600 mg; tinidazole tab 250 mg;500 mgalbendazole tab 200 mg (Albenza); praziquantel tab 600 mg (Biltricide); tinidazole tab 250 mg; 500 mg
    sulfamethoxazole-trimethoprim tab 400-80 mg; trimethoprim tab 100 mgsulfamethoxazole-trimethoprim; trimethoprim tab 100 mg (Trimethoprim)
    1–10 of 12
    1/2
    Urinary anti-infective (partial)mixed
    fosfomycin tromethamine powder pack 3 gmfosfomycin tromethamine powd pack 3 gm (Monurol)
    Vaccines (partial)mixed
    ABRYSVO RSV pre-fusion A&B vaccine recombinant for IM soln 120 mcg/0.5 mLABRYSVO rsv pre-fusion f a&b vac recomb for im soln 120 mcg/0.5ml
    FLUCELVAX 2025-2026 influenza virus vaccineFLUCELVAX 2025-2026 influenza virus vac tiss-cult subunit susp syr 0.5 ml pref
    AFLURIA 2025-2026 influenza virus vaccineAFLURIA 2025-2026 influenza virus vaccine split im susp
    FLUMIST nasal vaccine 202? (live intranasal)FLUMIST NASAL VACCINE influenza virus vaccine live intranasal liquid
    FLUZONE HIGH-DOSE 2025-20FLUZONE HIGH-DOSE 2025-20 influenza virus vac split high-dose pf susp syr 0.5ml pref
    AREXVY RSVpreF3 vaccine recomb adjuvanted IM 120 mcg/0.5mlAREXVY rsvpref3 vaccine recomb IBP adjuvanted for im susp 120 mcg/0.5ml
    BEXSERO meningococcal vaccine B prefilled syringeBEXSERO meningococcal vac b (recomb omv adjuv) inj prefilled syringe
    ACTHIB haemophilus b conjugate vaccine for injectionACTHIB haemophilus b polysaccharide conjugate vaccine for inj
    Vaccine product names / presentationsmixed
    No codes listed
    Product entries (no billing codes present)mixed
    No codes listed
    Listed drug strengths and formulationsmixed
    abemaciclib 50 mgVERZENIO abemaciclib tab 50
    sorafenib 200 mgsorafenib tosylate tab 200 mg (Nexavar)
    regorafenib 40 mgSTIVARGA regorafenib tab 40 mg
    sunitinib 12.5/25/37.5/50 mgsunitinib malate cap 12.5 mg; 25 mg; 37.5 mg; 50 mg (Sutent)
    dacomitinib 15/30/45 mgVIZIMPRO dacomitinib tab 15 mg, 30 mg, 45 mg
    vorasidenib 10/40 mgVORANIGO vorasidenib tab 10 mg, 40 mg
    crizotinib 20/50/150/200/250 mgXALKORI crizotinib cap sprinkle 20 mg, 50 mg, 150 mg; cap 200 mg, 250 mg
    capmatinib 150/200 mgTABRECTA capmatinib hcl tab 150 mg, 200 mg
    dabrafenib 50/75 mgTAFINLAR dabrafenib mesylate cap 50 mg; 75 mg
    enzalutamide 40/80 mgXTANDI enzalutamide cap/tab 40 mg, 80 mg
    1–10 of 26
    1/3
    Formulary drug listings (partial)mixed
    Drug names and strengthsMultiple contraceptives, progestins, and other formulations listed (e.g., norgestimate & ethinyl estradiol tab 0.25 mg-35 mcg; MEDROXYPROGESTERONE acetate im susp 150 mg/mL (Depo-Provera); norethindrone acetate tab 5 mg (Aygestin); progesterone cap 100 mg (Prometrium)).
    No billing codesmixed
    no codes presentThis section does not contain CPT/HCPCS/ICD-10/NDC codes — only product names and strengths.
    Antidiabetic drug listings (partial)mixed
    HUMULIN 70/30insulin NPH isophane & regular human injection (70/30) — various pen and vial forms listed
    TOUJEO MAX SOLOSTARinsulin glargine solution pen-injector 300 unit/mL (2 unit dial)
    TOUJEO SOLOSTARinsulin glargine solution pen-injector 300 unit/mL (1 unit dial)
    Additional insulin productsmixed
    NOVOLIN Ninsulin NPH (human) (isophane) injection 100 unit/mL; includes FLEXPEN and RELION pen forms
    TRESIBA / TRESIBA FLEXTOUCHinsulin degludec injectable (100 unit/mL) pen forms mentioned near NOVOLIN entries
    NOVOLIN 70/30insulin NPH & regular human injection 100 unit/mL (70/30) and FLEXPEN forms
    Thyroid, growth hormone, obstetric and bone agentsmixed
    SYNTHROIDlevothyroxine sodium tablets — strengths listed 25, 50, 75, 88, 100, 112, 125, 137, 150, 175 mcg
    GENOTROPINsomatropin for injection (various strengths) — listed in proximity to SYNTHROID
    OXYTOCICScategory header; methylergonovine maleate tab 0.2 mg listed
    alendronate sodiumoral solution 70 mg/7.5 mL and tablets 10 mg, 35 mg, 70 mg (Fosamax)
    Misc endocrine/metabolic drug listingsmixed
    JYNARQUEtolvaptan tablets (15 mg, 30 mg) referenced
    Cystadanebetaine powder for oral solution
    KERENDIAfinerenone tablets (10 mg) referenced
    Additional endocrine/metabolic agentsmixed
    Miacalcincalcitonin (salmon) nasal solution 200 unit/act
    Rocaltrolcalcitriol oral solution 1 mcg/mL and capsules 0.25 mcg
    Carbaglucarglumic acid soluble tablets 200 mg
    cinacalcet (SENSIPAR)cinacalcet HCl tablets 30 mg, 60 mg, 90 mg (base equivalents)
    somatropin brands (NORDITROPIN, OMNITROPE)somatropin solution pen-injector formulations listed
    Drugs listed (partial)mixed
    nitisinone cap 2 mg; 5 mg; 10 mg, 20 mgOrfadin (nitisinone) capsules listed
    cinacalcet hcl tab 30 mg, 60 mg, 90 mgSensipar (cinacalcet) tablets
    NORDITROPIN FLEXPRO somatropin penNorditropin somatropin pen formulations
    OMNITROPE somatropin for inj / solutionOmnitrope somatropin formulations
    clomiphene citrate tab 50 mgClomiphene tablets
    desmopressin acetate nasal spray 0.01%Desmopressin nasal spray formulation
    desmopressin acetate tab 0.1 mg; 0.2 mgDesmopressin tablets (DDAVP)
    ORFADIN nitisinone susp 4 mg/mLOrfadin suspension
    paricalcitol cap 1 mcg; 2 mcg; 4 mcgParicalcitol capsules
    FOLLISTIM AQ follitropin beta inj 300/0.36 mL; 600/0.72 mL; 900/1.08 mLFollistim AQ injections
    Drugs listed (partial)mixed
    ganirelix acetate soln prefilled syringe 250 mcg/0.5 mLGanirelix acetate
    PREGNYL chorionic gonadotropin for IM inj 10000 unitPregnyl HCG injection
    digoxin oral soln 0.05 mg/mL; digoxin tab 62.5 mcg; 125 mcg; 250 mcgDigoxin formulations
    risedronate sodium tab delayed release 35 mg; risedronate tab 5 mgRisedronate formulations including Atelvia
    sapropterin dihydrochloride powder packet 100 mg; 500 mg (Kuvan)Sapropterin (Kuvan)
    Drugs listed (partial)mixed
    SIGNIFOR pasireotide diaspartate IM/SC inj 0.3 mg/mL; 0.6 mg/mL; 0.9 mg/mLSignifor pasireotide injections
    isosorbide dinitrate tab 10 mg, 20 mg, 30 mgIsosorbide dinitrate tablets
    nitroglycerin oint 2%; nitroglycerin transdermal patches; nitroglycerin sl tab 0.3/0.4/0.6 mg; nitroglycerin spray 0.4 mg/sprayVarious nitroglycerin formulations (Nitro-Bid, Nitro-Dur, Nitrostat, Nitrolingual)
    sodium phenylbutyrate oral powder 3 g/teaspoonful; sodium phenylbutyrate tab 500 mg (Buphenyl)Sodium phenylbutyrate (Buphenyl)
    Drugs listed (partial)mixed
    SOMAVERT pegvisomant for injection 10 mg, 15 mg, 20 mg, 25 mg, 30 mgSomavert pegvisomant injections
    STRENSIQ asfotase alfa subcutaneous inj 18 mg/0.45 mLStrensiq asfotase alfa
    ranolazine tab ER 12 hr 500 mg; Ranexa 1000 mgRanolazine (Ranexa)
    SYNAREL nafarelin acetate nasal solution 2 mg/mL (200 mcg/act)Synarel nafarelin nasal solution
    Drugs listed (partial, includes cardiovascular agents)mixed
    BETA BLOCKERS (examples)Multiple beta blocker tablet strengths listed (acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol)
    tolvaptan tab 15 mg; 30 mg (Samsca)Tolvaptan tablets
    TYMLOS abaloparatide subcutaneous soln pen-injectorTymlos abaloparatide pen
    carvedilol tab 3.125 mg; 6.25 mg; 12.5 mg; 25 mg (Coreg)Carvedilol formulations
    Listed drugs and formulationsmixed
    tolvaptan tab 15 mg; 30 mg (Samsca)tolvaptan tab 15 mg; 30 mg (Samsca)
    carvedilol tab 3.125 mg; 6.25 mg; 12.5 mg; 25 mg (Coreg)carvedilol tab strengths listed
    TYMLOS abaloparatide subcutaneous soln pen-injectorTYMLOS abaloparatide subcutaneous soln pen-injector
    labetalol hcl tab 100 mg; 200 mg; 300 mglabetalol formulations and strengths
    metoprolol succinate tab ER 24 hr 25 mg; 50 mg; 100 mg; 200 mgextended release metoprolol strengths (Toprol XL)
    diltiazem hcl coated beads cap ER 24 hr 300 mg (Cardizem CD)diltiazem formulation listed
    metoprolol tartrate tab 25 mg; 37.5 mg; 75 mg; 50 mg; 100 mg (Lopressor)metoprolol tartrate strengths
    nadolol tab 20 mg; 40 mg; 80 mg (Corgard)nadolol strengths
    pindolol tab 5 mg; 10 mgpindolol strengths
    propranolol hcl cap ER 24 hr 60 mg; 80 mg; 120 mg; 160 mg (Inderal LA)propranolol LA strengths
    1–10 of 28
    1/3
    Specialty drug supply limit — 30-day
    Specialty supply limit30-day supply (specialty drugs are limited to a 30-day supply)
    Typical maintenance supplyUp to 90-day supply may be allowed for maintenance drugs (plan dependent)
    Member responsibility if over limitMember may be responsible for full cost if dispensed quantity exceeds dispensing limits

    Provider Requirements and Utilization Management

    Prior Authorization

    Prior authorization required when PA column indicated

    Some drugs on the Value Plus formulary require prior authorization; commonly required PAs are indicated with a dot in the Prior Authorization column of the drug list. Providers must submit an authorization request when a drug shows the PA indicator and follow any plan-specific authorization procedures.

    • If authorization is required, the provider must submit a request for coverage and receive approval before the drug will be covered.
    • Some plans may require additional authorizations beyond those noted in the formulary; verify the member's specific plan materials.
    Prior Authorization

    Check drug list UM indicators (PA, ST, QLL)

    The formulary drug list uses columns to indicate which utilization management programs apply: Prior Authorization, Step Therapy, and Quantity Level Limits. Presence of an indicator (dot) in a column means that the corresponding UM program applies to that drug.

    • Check Columns 4–6 on the drug list for PA, Step Therapy, and Quantity Level Limits indicators.
    • Verify the member's specific plan materials because some plans may have UM on additional drugs not indicated in this document.
    Note

    No PA rules in this antiviral/antiretroviral listing

    This segment of the formulary lists branded antiretroviral and antiviral products and formulations but does not specify prior authorization requirements for these entries. Providers should refer to the PA indicators on the drug list or the member's plan materials for authorization requirements.

    • Product names and strengths are listed without explicit PA rules in this excerpt.
    • Use the PA column on the full drug list to determine if authorization is required.
    Note

    Product names/strengths listed only — no PA specified

    The product listings in these chunks show drug names and strengths only and do not state prior authorization requirements in-text; providers must rely on the drug list PA column or the member's plan documents to determine PA applicability.

    • Listings present product names/strengths without embedded PA instructions.
    • Confirm PA status via the drug list columns or the member's benefit materials.
    Note

    Formulary listing: no PA rules stated here

    This formulary-style listing of drug names and presentations does not include explicit prior authorization rules in the text. Providers should check the PA indicator column on the drug list or plan-specific documentation to determine authorization needs.

    • No explicit PA rules are stated in these chunks; use the drug list columns for PA determination.
    • Some plans may require authorizations beyond what is shown in the formulary excerpt.
    Note

    Drug entries shown without PA instructions

    The text in these referenced chunks lists drug entries without stating prior authorization requirements; providers must consult the PA column on the drug list or the member's plan documents to determine if prior authorization is required.

    • No PA requirements are stated in these chunks' content.
    • Verify PA applicability using the formulary's PA column or plan materials.
    Note

    Formulary listing — no explicit PA rules in excerpt

    These formulary listings present drug names and formulations but do not include explicit prior authorization rules in this excerpt. Providers should rely on the drug list's PA column or the member's benefit details to confirm authorization requirements.

    • No explicit PA rules appear in this excerpt.
    • Check the PA indicator on the full drug list or plan-specific documentation.
    Note

    No PA instructions in this product/formulation listing

    No prior authorization requirements are specified in this segment; content is primarily product names, strengths, and presentations. Providers must use the PA column on the drug list or the member's plan materials to determine authorization obligations.

    • This segment lists products and strengths without PA instructions.
    • Confirm PA status via the formulary columns or benefit booklet.
    Note

    No PA instructions or codes provided here

    The listed chunks do not include prior authorization instructions or affected codes. Providers should check the PA indicator on the drug list or refer to the member's prescription plan materials to determine whether authorization is required.

    • No PA instructions or affected codes are listed in these chunks.
    • Use the drug list PA column and the member's plan materials for authorization requirements.
    Note

    PA not specified in these product listings

    Prior authorization requirements are not specified in these product listings. Providers must consult the formulary's Prior Authorization column or the member's plan documents to confirm whether PA is required for a given drug.

    • These chunks contain drug/strength/formulation listings without PA rules.
    • Confirm PA applicability through the drug list indicators or plan-specific materials.
    Note

    PA not specified — product listings only

    This segment contains enumerated drug names and formulations but does not state prior authorization requirements. Providers should refer to the PA column on the drug list or the member's prescription plan documents to determine if authorization is needed.

    • No PA requirements stated in this segment; only product names/formulations are listed.
    • Verify PA via the formulary columns or the member's benefit booklet.
    Note

    No PA stated in this listing

    No prior authorization requirements are specified in these chunks; they present drug names and formulations only. Providers must check the PA indicator on the formulary or the member's plan materials for authorization guidance.

    • This excerpt lists drug products without PA rules.
    • Use the drug list PA column or plan materials to determine authorization needs.
    Note

    PA not specified in this excerpt

    These chunks list drugs and formulations without stating prior authorization requirements. Providers should confirm PA requirements by checking the PA column on the drug list or the member's specific plan documentation.

    • No explicit PA requirement is described in these chunks.
    • Confirm authorization needs using the formulary columns or benefit documents.
    Note
    Note
    Step Therapy

    Follow step therapy when Step Therapy column indicated

    Step therapy may require trying a proven, cost‑effective alternative before coverage is available for certain drugs; drugs commonly requiring step therapy are marked with a dot in the Step Therapy column of the drug list. Providers must follow step therapy program requirements when the Step Therapy indicator is present.

    • If the Step Therapy column shows an indicator, the pharmacy step therapy program applies and prior trials of specified alternatives may be required.
    • Refer to the member's plan materials for any plan‑specific step therapy details.
    Step Therapy

    Check drug list for Step Therapy indicator

    Step therapy applicability is shown on the drug list: if the Step Therapy column contains an indicator (dot), the pharmacy step therapy program applies to that prescription. Providers should verify the Step Therapy indicator before prescribing.

    • Check Columns 4–6 on the drug list (including Step Therapy) to see if step therapy applies.
    • Some plans may include step therapy on additional drugs beyond those shown here; confirm with the member's plan materials.
    Note

    No step therapy rules in this product listing

    These product name–only chunks do not provide step therapy rules. Providers must consult the formulary's Step Therapy column or the member's plan materials to determine whether step therapy applies to a given drug.

    • No step therapy rules are provided in these chunks; only product names and strengths are listed.
    • Determine step therapy applicability via the drug list columns or benefit booklet.
    Note

    Product listings only — provider actions not specified

    Product names and strengths are listed without provider action details in these chunks. Providers should consult the formulary columns and member plan documents for PA, step therapy, and quantity limit requirements related to these drugs.

    • No explicit PA/step therapy rules are present in these entries.
    • Use the drug list UM indicator columns and the member's plan materials for requirements.
    Note

    No UM or documentation instructions in these listings

    These chunks list drugs and formulations but do not include prior authorization, step therapy, or documentation instructions. Providers must reference the drug list columns and the member's plan materials to determine any required actions.

    • No PA/step therapy/documentation requirements present in these chunks.
    • Verify UM and documentation obligations via the formulary columns or benefit booklet.
    Note

    No explicit authorization triggers shown here

    This segment contains product entries without explicit authorization or denial triggers. Providers should use the PA/Step Therapy/Quantity Limits columns on the drug list and the member's plan documents to determine required actions and potential denial risks.

    • No explicit authorization or denial criteria are provided in this excerpt.
    • Confirm any UM program applicability using the formulary indicator columns and plan materials.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    Formulary tier reconsideration and appeals — submit request to P&T

    These chunks provide drug/formulation listings without documentation requirements for coverage or submission. When documentation is required (e.g., for PA or exception requests), providers must follow the plan's instructions and submit necessary clinical information.

    • No documentation requirements are stated in these chunks; they are product listings.
    • For PA or nonformulary exception requests, provide clinical justification per plan procedures.
    Documentation Required

    Submit nonformulary (formulary exception) request on member's behalf

    To request coverage for a nonformulary drug, the provider must submit a nonformulary consideration (formulary exception) request on behalf of the member. Exception requests are required for drugs not listed on the formulary to be considered for coverage.

    • Providers must submit the nonformulary consideration request on the member's behalf.
    • Nonformulary exceptions entail review and follow the dispute and appeal process if patient‑specific review is requested.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Denial Risk

    Coverage subject to PA, ST, QLL — failure to obtain PA may cause denial

    Coverage is subject to utilization management programs including prior authorization, step therapy, and quantity level limits; failure to obtain required prior authorization may result in denial of coverage.

    • If an authorization is required and not obtained, the drug may be denied.
    • Quantity above permitted limits may be the member's financial responsibility if dispensed beyond the limit.
    Denial Risk

    Nonformulary drugs are not covered without approved exception

    Prescriptions for drugs that are not listed on the formulary are not covered unless a nonformulary (formulary exception) request is approved; providers should submit exception requests on behalf of members when appropriate.

    • Nonformulary drugs may be denied if no exception is approved.
    • Providers must submit a nonformulary consideration request to seek coverage for drugs not on the formulary.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Policy Background

    The Value Plus Formulary is maintained and reviewed by the Capital Blue Cross Pharmacy & Therapeutics (P&T) Committee, which is composed of practicing providers and pharmacists responsible for evaluating drugs for safety and effectiveness.

    Definitions and Abbreviations

    Specialty drugs — distributed through plan's specialty pharmacy; complex conditions
    DefinitionDrugs used to treat complex medical conditions (e.g., hepatitis, multiple sclerosis, rheumatoid arthritis); may be oral or injectable and self-administered.
    DistributionDistributed through the plan's contracted specialty pharmacy (Accredo)
    Limited distributionSome specialty drugs are limited distribution and may only be dispensed by select pharmacies
    Member supportMembers can contact Accredo at 833.721.1626 (TTY: 711) or fax 888.302.1028 or set up service online
    Generic substitution policies — mandatory, restricted, voluntary
    Mandatory generic substitutionIf a generic is available, member who requests brand or provider indicates DAW may pay cost difference plus applicable brand copay/coinsurance (plan-specific)
    Restricted generic substitutionIf a generic is available and member requests brand, member pays cost difference plus applicable brand copay/coinsurance; if provider indicates DAW, member pays brand copay/coinsurance without cost-difference
    Voluntary generic substitutionMember pays only the applicable copayment and/or coinsurance for the brand-name drug when voluntary substitution applies
    Abbreviation key — dosage form and strength abbreviations
    capcapsules
    tabtablets
    mgmilligram
    suspsuspension
    injinjection
    Rapid-Acting Insulins — group label used to classify products (e.g., insulin aspart, lispro)
    Group labelRapid-Acting Insulins — used to classify products such as insulin aspart and insulin lispro
    Example productsFIASP (insulin aspart with niacinamide); NOVOLOG (insulin aspart) — listed as rapid/short-acting formulations
    Presentation typesPen, vial, cartridge and prefilled injector presentations are included
    Basal/Intermediate-Acting Insulins — group label for longer-acting insulins (NPH, glargine)
    Group labelBasal/Intermediate-Acting Insulins — group label for longer-acting insulins such as NPH and insulin glargine
    Example productsLANTUS (insulin glargine), TOUJEO (insulin glargine 300 unit/mL), HUMULIN N / NOVOLIN N (NPH) — listed under basal/intermediate insulins
    PresentationsPens, vials, and cartridge formulations are included in listings

    Step Therapy Rules

    RequirementHow it's indicated on the drug list
    Step therapy may be required for certain drugs
    Indicated on the drug list with a dot in the Step Therapy column

    Quantity Level Limits

    Quantity level limits as noted on drug list (per prescription or time period); state dispensing limits may also apply
    Quantity level limitsQuantity level limits are noted on the drug list and may apply per prescription or over a defined time period
    State dispensing limitsState dispensing laws may further restrict quantities dispensed (e.g., controlled substances) and apply in addition to plan limits
    Member financial responsibilityIf provider prescribes greater quantity than allowed, member may be responsible for full cost beyond coverage

    Specialty Pharmacy and Distribution

    Note

    Specialty drugs dispensed via Accredo (plan specialty pharmacy)

    Specialty drugs are dispensed through the plan's contracted specialty pharmacy, Accredo; limited distribution drugs may restrict which pharmacies can dispense them. Providers and members can contact Accredo for initiation or distribution details.

    • Call Accredo at 833.721.1626 (TTY: 711) or fax 888.302.1028 for specialty distribution and billing information.
    • Limited Distribution indicates restrictions on which pharmacies may dispense a drug; members may be required to use another pharmacy for limited distribution drugs.